Speech and language outcome measures in clinical trials of Alzheimer's and Parkinson's diseases.
Speech and language outcome measures in clinical trials of Alzheimer's and Parkinson's diseases.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Málaga, ES · Author affiliation
Cognitive Neuroscience and Aphasia Unit, Faculty of Psychology and Speech Therapy, University of Málaga, Málaga, Spain.Location evidence
Victoria, AR · Author affiliation
Cognitive Neuroscience Center, Universidad de San Andrés, Victoria, Argentina.Location evidence
Medellín, CO · Author affiliation
GITA Lab, Faculty of Engineering, University of Antioquia, Medellín, Colombia.Location evidence
Erlangen, DE · Author affiliation
LME Lab, Faculty of Engineering, University of Erlangen-Nürnberg, Erlangen, Germany.Location evidence
San Francisco, US · Author affiliation
Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, USA; and Trinity College Dublin, Dublin, Ireland.Location evidence
IE · Author affiliation · country only
Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, USA; and Trinity College Dublin, Dublin, Ireland.Location evidence
Santiago, CL · Author affiliation
Departamento de Lingüística y Literatura, Facultad de Humanidades, Universidad de Santiago de Chile, Santiago, Chile.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
INTRODUCTION: Alongside core diagnostic symptoms, Alzheimer's disease (AD) and Parkinson's disease (PD) involve early and pervasive speech-language impairments (SLI), often appearing in preclinical stages and capturing disease severity. However, speech language outcome measures are under-represented in clinical trials, missing out on critical clinical outcome assessments (COAs). AREAS COVERED: The purpose of this review is to survey the findings from classical (analogical) and novel (digital) speech-language measures as pathways toward more precise diagnosis and response to treatment indices in interventional clinical trials. This narrative review covers two main areas; first, it examines the strengths and limitations of SL measures in traditional cognitive testing scales to identify adequate COAs for AD and PD. Second, it overviews findings on classical and digital COAs that hold great promise despite their widespread absence in clinical trials. EXPERT OPINION: Incorporating strategic SL COAs in clinical trials may identify early, severity-sensitive deficits and enhance the clinical insights thus obtained. The modification of clinical trial designs will nevertheless be required to increase sensitivity to identify meaningful clinical outcomes.